Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 14/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.47 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870583 | 0.89 | AOC3 (0.61) | AOC3ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL14019545 | 0.86 | AOC3 (0.55) | AOC3ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL14045057 | 0.80 | AOC3 (0.56) | AOC3 | |
| SCHEMBL14215639 | 0.79 | AOC3 (0.57) | AOC3 | |
| SCHEMBL14044988 | 0.79 | AOC3 (0.60) | AOC3 | |
| SCHEMBL14045043 | 0.79 | AOC3 (0.55) | AOC3 | |
| SCHEMBL13559407 | 0.77 | AOC3 (0.55) | AOC3 | |
| SCHEMBL4871182 | 0.76 | AOC3 (1.00) | AOC3ADRA2AADRA2BADRA2C | |
| SCHEMBL14045058 | 0.73 | AOC3 (0.58) | AOC3 | |
| SCHEMBL14045061 | 0.73 | AOC3 (0.55) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | AOC3 202/4885ADRA2A 2484/4885ADRA2B 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.